Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

The journal of pathology. Clinical research

Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ, Pinder S, van Deurzen CH, Jones L, Sironen R, Visscher D, Caldas C, Daley F, Coulson P, Broeks A, Sanders J, Wesseling J, Nevanlinna H, Fagerholm R, Blomqvist C, Heikkilä P, Ali HR, Dawson SJ, Figueroa J, Lissowska J, Brinton L, Mannermaa A, Kataja V, Kosma VM, Cox A, Brock IW, Cross SS, Reed MW, Couch FJ, Olson JE, Devillee P, Mesker WE, Seyaneve CM, Hollestelle A, Benitez J, Perez JI, Menéndez P, Bolla MK, Easton DF, Schmidt MK, Pharoah PD, Sherman ME, García-Closas M.
PMID: 27499890
J Pathol Clin Res. 2014 Dec 04;1(1):18-32. doi: 10.1002/cjp2.3. eCollection 2015 Jan.

Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized scoring methods. To...

Cite
Howat WJ, Blows FM, Provenzano E, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2014;1(1):18-32doi: 10.1002/cjp2.3.
Howat, W. J., Blows, F. M., Provenzano, E., Brook, M. N., Morris, L., Gazinska, P., Johnson, N., McDuffus, L. A., Miller, J., Sawyer, E. J., Pinder, S., van Deurzen, C. H., Jones, L., Sironen, R., Visscher, D., Caldas, C., Daley, F., Coulson, P., Broeks, A., Sanders, J., Wesseling, J., Nevanlinna, H., Fagerholm, R., Blomqvist, C., Heikkilä, P., Ali, H. R., Dawson, S. J., Figueroa, J., Lissowska, J., Brinton, L., Mannermaa, A., Kataja, V., Kosma, V. M., Cox, A., Brock, I. W., Cross, S. S., Reed, M. W., Couch, F. J., Olson, J. E., Devillee, P., Mesker, W. E., Seyaneve, C. M., Hollestelle, A., Benitez, J., Perez, J. I., Menéndez, P., Bolla, M. K., Easton, D. F., Schmidt, M. K., Pharoah, P. D., Sherman, M. E., & García-Closas, M. (2015). Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The journal of pathology. Clinical research, 1(1), 18-32. https://doi.org/10.1002/cjp2.3
Howat, William J, et al. "Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium." The journal of pathology. Clinical research vol. 1,1 (2015): 18-32. doi: https://doi.org/10.1002/cjp2.3
Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, Johnson N, McDuffus LA, Miller J, Sawyer EJ, Pinder S, van Deurzen CH, Jones L, Sironen R, Visscher D, Caldas C, Daley F, Coulson P, Broeks A, Sanders J, Wesseling J, Nevanlinna H, Fagerholm R, Blomqvist C, Heikkilä P, Ali HR, Dawson SJ, Figueroa J, Lissowska J, Brinton L, Mannermaa A, Kataja V, Kosma VM, Cox A, Brock IW, Cross SS, Reed MW, Couch FJ, Olson JE, Devillee P, Mesker WE, Seyaneve CM, Hollestelle A, Benitez J, Perez JI, Menéndez P, Bolla MK, Easton DF, Schmidt MK, Pharoah PD, Sherman ME, García-Closas M. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2014 Dec 04;1(1):18-32. doi: 10.1002/cjp2.3. eCollection 2015 Jan. PMID: 27499890; PMCID: PMC4858117.
Copy Download .nbib Format: NLM
Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios.

Cancer informatics

Karchin R, Agarwal M, Sali A, Couch F, Beattie MS.
PMID: 19043619
Cancer Inform. 2008;6:203-16. doi: 10.4137/cin.s618. Epub 2008 Apr 18.

BACKGROUND: Missense (amino-acid changing) variants found in cancer predisposition genes often create difficulties when clinically interpreting genetic testing results. Although bioinformatics has developed approaches to predicting the impact of these variants, many of these approaches have not been readily...

Cite
Karchin R, Agarwal M, Sali A, et al. Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer Inform. 2008;6:203-16doi: 10.4137/cin.s618.
Karchin, R., Agarwal, M., Sali, A., Couch, F., & Beattie, M. S. (2008). Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer informatics, 6203-16. https://doi.org/10.4137/cin.s618
Karchin, Rachel, et al. "Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios." Cancer informatics vol. 6 (2008): 203-16. doi: https://doi.org/10.4137/cin.s618
Karchin R, Agarwal M, Sali A, Couch F, Beattie MS. Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer Inform. 2008;6:203-16. doi: 10.4137/cin.s618. Epub 2008 Apr 18. PMID: 19043619; PMCID: PMC2587343.
Copy Download .nbib Format: NLM
Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.

Cancer research

Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi J, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby LA, Baur JA, Jang MH.
PMID: 33771896
Cancer Res. 2021 Jul 01;81(13):3727-3737. doi: 10.1158/0008-5472.CAN-20-3290. Epub 2021 Mar 26.

Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic understanding underlying CICI pathophysiology....

Cite
Yoo KH, Tang JJ, Rashid MA, et al. Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Res. 2021;81(13):3727-3737doi: 10.1158/0008-5472.CAN-20-3290.
Yoo, K. H., Tang, J. J., Rashid, M. A., Cho, C. H., Corujo-Ramirez, A., Choi, J., Bae, M. G., Brogren, D., Hawse, J. R., Hou, X., Weroha, S. J., Oliveros, A., Kirkeby, L. A., Baur, J. A., & Jang, M. H. (2021). Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer research, 81(13), 3727-3737. https://doi.org/10.1158/0008-5472.CAN-20-3290
Yoo, Ki Hyun, et al. "Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments." Cancer research vol. 81,13 (2021): 3727-3737. doi: https://doi.org/10.1158/0008-5472.CAN-20-3290
Yoo KH, Tang JJ, Rashid MA, Cho CH, Corujo-Ramirez A, Choi J, Bae MG, Brogren D, Hawse JR, Hou X, Weroha SJ, Oliveros A, Kirkeby LA, Baur JA, Jang MH. Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer Res. 2021 Jul 01;81(13):3727-3737. doi: 10.1158/0008-5472.CAN-20-3290. Epub 2021 Mar 26. PMID: 33771896; PMCID: PMC8277702.
Copy Download .nbib Format: NLM
Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.

Endocrinology

Jayaraman S, Reid JM, Hawse JR, Goetz MP.
PMID: 34480554
Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191.

The selective estrogen receptor (ER) modulator, tamoxifen, is the only endocrine agent with approvals for both the prevention and treatment of premenopausal and postmenopausal estrogen-receptor positive breast cancer as well as for the treatment of male breast cancer. Endoxifen,...

Cite
Jayaraman S, Reid JM, Hawse JR, et al. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021;162(12)doi: 10.1210/endocr/bqab191.
Jayaraman, S., Reid, J. M., Hawse, J. R., & Goetz, M. P. (2021). Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology, 162(12), . https://doi.org/10.1210/endocr/bqab191
Jayaraman, Swaathi, et al. "Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside." Endocrinology vol. 162,12 (2021). doi: https://doi.org/10.1210/endocr/bqab191
Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab191. PMID: 34480554.
Copy Download .nbib Format: NLM
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP.
PMID: 34108182
Clin Cancer Res. 2021 Oct 15;27(20):5628-5637. doi: 10.1158/1078-0432.CCR-21-0343. Epub 2021 Jun 09.

PURPOSE: Programmed death ligand 1 [PD-(L)1]-targeted therapies have shown modest survival benefit in triple-negative breast cancer (TNBC). PD-L1EXPERIMENTAL DESIGN: From a large cohort of chemotherapy-naïve TNBC, clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME (Nanostring GeoMX)...

Cite
Carter JM, Polley MC, Leon-Ferre RA, et al. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021;27(20):5628-5637doi: 10.1158/1078-0432.CCR-21-0343.
Carter, J. M., Polley, M. C., Leon-Ferre, R. A., Sinnwell, J., Thompson, K. J., Wang, X., Ma, Y., Zahrieh, D., Kachergus, J. M., Solanki, M., Boughey, J. C., Liu, M. C., Ingle, J. N., Kalari, K. R., Couch, F. J., Thompson, E. A., & Goetz, M. P. (2021). Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5628-5637. https://doi.org/10.1158/1078-0432.CCR-21-0343
Carter, Jodi M, et al. "Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5628-5637. doi: https://doi.org/10.1158/1078-0432.CCR-21-0343
Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021 Oct 15;27(20):5628-5637. doi: 10.1158/1078-0432.CCR-21-0343. Epub 2021 Jun 09. PMID: 34108182.
Copy Download .nbib Format: NLM
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Journal of the National Cancer Institute

Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA.
PMID: 33159444
J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160.

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants...

Cite
Ruddy KJ, Schaid DJ, Batzler A, et al. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021;113(8):1105-1108doi: 10.1093/jnci/djaa160.
Ruddy, K. J., Schaid, D. J., Batzler, A., Cecchini, R. S., Partridge, A. H., Norman, A., Fehrenbacher, L., Stewart, E. A., Trabuco, E., Ginsburg, E., Couch, F. J., Fasching, P. A., Vachon, C., & Ganz, P. A. (2021). Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 113(8), 1105-1108. https://doi.org/10.1093/jnci/djaa160
Ruddy, Kathryn J, et al. "Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea." Journal of the National Cancer Institute vol. 113,8 (2021): 1105-1108. doi: https://doi.org/10.1093/jnci/djaa160
Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160. PMID: 33159444; PMCID: PMC8328977.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 10.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2021). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. (2021). doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 10. PMID: 34902335.
Copy Download .nbib Format: NLM
Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Yadav S, Hu C, Nathanson KL, Weitzel JN, Goldgar DE, Kraft P, Gnanaolivu RD, Na J, Huang H, Boddicker NJ, Larson N, Gao C, Yao S, Weinberg C, Vachon CM, Trentham-Dietz A, Taylor JA, Sandler DR, Patel A, Palmer JR, Olson JE, Neuhausen S, Martinez E, Lindstrom S, Lacey JV, Kurian AW, John EM, Haiman C, Bernstein L, Auer PW, Anton-Culver H, Ambrosone CB, Karam R, Chao E, Yussuf A, Pesaran T, Dolinsky JS, Hart SN, LaDuca H, Polley EC, Domchek SM, Couch FJ.
PMID: 34672684
J Clin Oncol. 2021 Dec 10;39(35):3918-3926. doi: 10.1200/JCO.21.00640. Epub 2021 Oct 21.

PURPOSE: To determine the contribution of germline pathogenic variants (PVs) in hereditary cancer testing panel genes to invasive lobular carcinoma (ILC) of the breast.MATERIALS AND METHODS: The study included 2,999 women with ILC from a population-based cohort and 3,796...

Cite
Yadav S, Hu C, Nathanson KL, et al. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. J Clin Oncol. 2021;39(35):3918-3926doi: 10.1200/JCO.21.00640.
Yadav, S., Hu, C., Nathanson, K. L., Weitzel, J. N., Goldgar, D. E., Kraft, P., Gnanaolivu, R. D., Na, J., Huang, H., Boddicker, N. J., Larson, N., Gao, C., Yao, S., Weinberg, C., Vachon, C. M., Trentham-Dietz, A., Taylor, J. A., Sandler, D. R., Patel, A., Palmer, J. R., Olson, J. E., Neuhausen, S., Martinez, E., Lindstrom, S., Lacey, J. V., Kurian, A. W., John, E. M., Haiman, C., Bernstein, L., Auer, P. W., Anton-Culver, H., Ambrosone, C. B., Karam, R., Chao, E., Yussuf, A., Pesaran, T., Dolinsky, J. S., Hart, S. N., LaDuca, H., Polley, E. C., Domchek, S. M., & Couch, F. J. (2021). Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(35), 3918-3926. https://doi.org/10.1200/JCO.21.00640
Yadav, Siddhartha, et al. "Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,35 (2021): 3918-3926. doi: https://doi.org/10.1200/JCO.21.00640
Yadav S, Hu C, Nathanson KL, Weitzel JN, Goldgar DE, Kraft P, Gnanaolivu RD, Na J, Huang H, Boddicker NJ, Larson N, Gao C, Yao S, Weinberg C, Vachon CM, Trentham-Dietz A, Taylor JA, Sandler DR, Patel A, Palmer JR, Olson JE, Neuhausen S, Martinez E, Lindstrom S, Lacey JV, Kurian AW, John EM, Haiman C, Bernstein L, Auer PW, Anton-Culver H, Ambrosone CB, Karam R, Chao E, Yussuf A, Pesaran T, Dolinsky JS, Hart SN, LaDuca H, Polley EC, Domchek SM, Couch FJ. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. J Clin Oncol. 2021 Dec 10;39(35):3918-3926. doi: 10.1200/JCO.21.00640. Epub 2021 Oct 21. PMID: 34672684; PMCID: PMC8660003.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;23(1):149-160doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2022). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, 23(1), 149-160. https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. 23,1 (2022): 149-160. doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. PMID: 34902335.
Copy Download .nbib Format: NLM
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

The Lancet. Oncology

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
PMID: 34902335
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.

BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across...

Cite
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021;23(1):149-160doi: 10.1016/S1470-2045(21)00589-1.
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., López-Tarruella, S., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S. J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M. O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F. (2022). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet. Oncology, 23(1), 149-160. https://doi.org/10.1016/S1470-2045(21)00589-1
Yau, Christina, et al. "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients." The Lancet. Oncology vol. 23,1 (2022): 149-160. doi: https://doi.org/10.1016/S1470-2045(21)00589-1
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. PMID: 34902335.
Copy Download .nbib Format: NLM
Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.

Cancer informatics

Cichon MA, Nelson CM, Radisky DC.
PMID: 25698877
Cancer Inform. 2015 Feb 09;14:1-13. doi: 10.4137/CIN.S18965. eCollection 2015.

Epithelial-mesenchymal transition (EMT) is a physiological program that is activated during cancer cell invasion and metastasis. We show here that EMT-related processes are linked to a broad and conserved program of transcriptional alterations that are influenced by cell contact...

Cite
Cichon MA, Nelson CM, Radisky DC. Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer Inform. 2015;14:1-13doi: 10.4137/CIN.S18965.
Cichon, M. A., Nelson, C. M., & Radisky, D. C. (2015). Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer informatics, 141-13. https://doi.org/10.4137/CIN.S18965
Cichon, Magdalena A, et al. "Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion." Cancer informatics vol. 14 (2015): 1-13. doi: https://doi.org/10.4137/CIN.S18965
Cichon MA, Nelson CM, Radisky DC. Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer Inform. 2015 Feb 09;14:1-13. doi: 10.4137/CIN.S18965. eCollection 2015. PMID: 25698877; PMCID: PMC4325704.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, Maguire P, Kremeyer B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Beckmann MW, Blomqvist C, Blot W, Boeckx B, Bojesen SE, Bonanni B, Brand JS, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Cai Q, Chang-Claude J, Couch FJ, Cox A, Cross SS, Deming-Halverson SL, Devilee P, Dos-Santos-Silva I, Dörk T, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Guo Q, Gündert M, Haiman CA, Hallberg E, Hamann U, Harrington P, Hooning MJ, Hopper JL, Huang G, Jakubowska A, Jones ME, Kerin MJ, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Lubinski J, Mannermaa A, Martens JWM, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Peto J, Pylkäs K, Radice P, Rhenius V, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Simard J, Southey MC, Swerdlow AJ, Truong T, Wendt C, Winqvist R, Zheng W, Benitez J, Dunning AM, Pharoah PDP, Easton DF, Czene K, Hall P, Lindblom A.
PMID: 29262523
Oncotarget. 2017 Oct 12;8(61):102769-102782. doi: 10.18632/oncotarget.21800. eCollection 2017 Nov 28.

Most non-

Cite
Jiao X, Aravidis C, Marikkannu R, et al. . Oncotarget. 2017;8(61):102769-102782doi: 10.18632/oncotarget.21800.
Jiao, X., Aravidis, C., Marikkannu, R., Rantala, J., Picelli, S., Adamovic, T., Liu, T., Maguire, P., Kremeyer, B., Luo, L., von Holst, S., Kontham, V., Thutkawkorapin, J., Margolin, S., Du, Q., Lundin, J., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Lush, M., Ambrosone, C. B., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Beckmann, M. W., Blomqvist, C., Blot, W., Boeckx, B., Bojesen, S. E., Bonanni, B., Brand, J. S., Brauch, H., Brenner, H., Broeks, A., Brüning, T., Burwinkel, B., Cai, Q., Chang-Claude, J., Couch, F. J., Cox, A., Cross, S. S., Deming-Halverson, S. L., Devilee, P., Dos-Santos-Silva, I., Dörk, T., Eriksson, M., Fasching, P. A., Figueroa, J., Flesch-Janys, D., Flyger, H., Gabrielson, M., García-Closas, M., Giles, G. G., González-Neira, A., Guénel, P., Guo, Q., Gündert, M., Haiman, C. A., Hallberg, E., Hamann, U., Harrington, P., Hooning, M. J., Hopper, J. L., Huang, G., Jakubowska, A., Jones, M. E., Kerin, M. J., Kosma, V. M., Kristensen, V. N., Lambrechts, D., Le Marchand, L., Lubinski, J., Mannermaa, A., Martens, J. W. M., Meindl, A., Milne, R. L., Mulligan, A. M., Neuhausen, S. L., Nevanlinna, H., Peto, J., Pylkäs, K., Radice, P., Rhenius, V., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Seynaeve, C., Shah, M., Simard, J., Southey, M. C., Swerdlow, A. J., Truong, T., Wendt, C., Winqvist, R., Zheng, W., Benitez, J., Dunning, A. M., Pharoah, P. D. P., Easton, D. F., Czene, K., Hall, P., & Lindblom, A. (2017). . Oncotarget, 8(61), 102769-102782. https://doi.org/10.18632/oncotarget.21800
Jiao, Xiang, et al. "." Oncotarget vol. 8,61 (2017): 102769-102782. doi: https://doi.org/10.18632/oncotarget.21800
Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, Maguire P, Kremeyer B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Beckmann MW, Blomqvist C, Blot W, Boeckx B, Bojesen SE, Bonanni B, Brand JS, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Cai Q, Chang-Claude J, Couch FJ, Cox A, Cross SS, Deming-Halverson SL, Devilee P, Dos-Santos-Silva I, Dörk T, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Guo Q, Gündert M, Haiman CA, Hallberg E, Hamann U, Harrington P, Hooning MJ, Hopper JL, Huang G, Jakubowska A, Jones ME, Kerin MJ, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Lubinski J, Mannermaa A, Martens JWM, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Peto J, Pylkäs K, Radice P, Rhenius V, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Simard J, Southey MC, Swerdlow AJ, Truong T, Wendt C, Winqvist R, Zheng W, Benitez J, Dunning AM, Pharoah PDP, Easton DF, Czene K, Hall P, Lindblom A. . Oncotarget. 2017 Oct 12;8(61):102769-102782. doi: 10.18632/oncotarget.21800. eCollection 2017 Nov 28. PMID: 29262523; PMCID: PMC5732689.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries